Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (UG3/UH3)
Closed Posted
- Opportunity number
- RFA-CA-19-012
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Categories
-
- Education
- Environment
- Health
- Eligible applicants
-
- Independent School Districts
- 501(c)(3) Nonprofits
- State Governments
- Public or Indian Housing Auth.
- City/Township Governments
- Special District Governments
- County Governments
- Other
- Higher Education Inst. (Public)
- For Profit Organizations
- Small Businesses
- Tribal Organizations (Not Federally Recognized)
- Non-501(c)(3) Nonprofits
- Higher Education Inst. (Private)
- Tribal Governments (Federally Recognized)
- Full announcement
Opportunity details come from Grants.gov. Updated .
Synopsis
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support UG3/UH3 phased award Projects as part of the expanded Immuno-Oncology Translational Network (IOTN). The IOTN will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor initiation and progression and evaluating new or improved immunopreventive and immunotherapeutic strategies (including combinations with standard or other therapies). Studies should be largely pre-clinical involving clinically-relevant models and endpoints, and have the potential for rapid translation into early-phase clinical applications. Applicants responding to this FOA must apply for both the UG3 and UH3 phases together in a single application. Exploratory studies aimed at immune target identification and validation will be supported under UG3. Achievement of the UH2 milestones will be necessary for transition to the UH3 Implementation Phase. UH3 phase may be awarded after administrative review of the UH2 milestones. Provided these milestones are achieved, UH3 phase may continue with development and preclinical testing of specific interventions.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Files
| File | Type | Posted |
|---|---|---|
| PKG00246003-instructions.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity